
Incannex Healthcare Ltd (NASDAQ:IXHL) is soaring Tuesday on abnormally-high volume. The stock has been extremely volatile since the company released a preliminary analysis of data from its phase 2 clinical trial investigating its novel cannabinoid combination product, IHL-42X, for the treatment of obstructive sleep apnoea.
Related Link: Incannex Clinical Trial Shows Notable Reduction In The Apnoea Hypopnoea Index With Novel Cannabinoid Product